sirukumab

Home
Ligands
sirukumab

GtoPdb Ligand ID: 7989

Synonyms: CNTO 136 | CNTO-136 | Plivensia (proposed trade name)

Comment: Sirukumab is a monoclonal antibody directed against interleukin 6 (IL-6), in development as an immunomodulator for the treatment of rheumatoid arthritis (RA). It is also being tested as an immunopsychiatry therapy to treat depression.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence BLAST search using the heavy chain variable region of sirukumab provides100% match to a sequence claimed in patent US7560112 [1], and to the antibody with designation AME-19a.

References
1. Chen Y, Gardner D, Knight DM, Lark MW, Liang B, Shealy DJ, Song X-yR, Stojanovic-Susulic V, Sweet RW, Tam SH et al.. (2009) Anti-il-6 antibodies, compositions, methods and uses. Patent number: US7560112. Assignee: Applied Molecular Evolution, Inc., Centocor Ortho Biotech Inc.. Priority date: 29/04/2005. Publication date: 14/07/2009.
2. Du Preez A, Leveson J, Zunszain PA, Pariante CM. (2016) Inflammatory insults and mental health consequences: does timing matter when it comes to depression?. Psychol Med, 46 (10): 2041-57. [PMID:27181594]
3. Hepgul N, Cattaneo A, Agarwal K, Baraldi S, Borsini A, Bufalino C, Forton DM, Mondelli V, Nikkheslat N, Lopizzo N et al.. (2016) Transcriptomics in Interferon-α-Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression. Neuropsychopharmacology, 41 (10): 2502-11. [PMID:27067128]
4. Money KM, Olah Z, Korade Z, Garbett KA, Shelton RC, Mirnics K. (2016) An altered peripheral IL6 response in major depressive disorder. Neurobiol Dis, 89: 46-54. [PMID:26804030]
5. Nishimoto N. (2006) Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol, 18 (3): 277-81. [PMID:16582692]
6. Rovin BH, van Vollenhoven RF, Aranow C, Wagner C, Gordon R, Zhuang Y, Belkowski S, Hsu B. (2016) A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. Arthritis Rheumatol, 68 (9): 2174-83. [PMID:27110697]
7. Sun Y, Wang D, Salvadore G, Hsu B, Curran M, Casper C, Vermeulen J, Kent JM, Singh J, Drevets WC et al.. (2017) The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease. Brain Behav Immun, 66: 156-164. [PMID:28676350]
8. Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, Davis HM, Zhou H. (2011) Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol, 72 (2): 270-81. [PMID:21392075]
9. Young JJ, Bruno D, Pomara N. (2014) A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord, 169: 15-20. [PMID:25128861]
10. Zhang C, Wu Z, Zhao G, Wang F, Fang Y. (2016) Identification of IL6 as a susceptibility gene for major depressive disorder. Sci Rep, 6: 31264. [PMID:27502736]

References

1. Chen Y, Gardner D, Knight DM, Lark MW, Liang B, Shealy DJ, Song X-yR, Stojanovic-Susulic V, Sweet RW, Tam SH et al.. (2009)
Anti-il-6 antibodies, compositions, methods and uses.
Patent number: US7560112. Assignee: Applied Molecular Evolution, Inc., Centocor Ortho Biotech Inc.. Priority date: 29/04/2005. Publication date: 14/07/2009.

2. Du Preez A, Leveson J, Zunszain PA, Pariante CM. (2016)
Inflammatory insults and mental health consequences: does timing matter when it comes to depression?.
Psychol Med, 46 (10): 2041-57. [PMID:27181594]

3. Hepgul N, Cattaneo A, Agarwal K, Baraldi S, Borsini A, Bufalino C, Forton DM, Mondelli V, Nikkheslat N, Lopizzo N et al.. (2016)
Transcriptomics in Interferon-α-Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression.
Neuropsychopharmacology, 41 (10): 2502-11. [PMID:27067128]

4. Money KM, Olah Z, Korade Z, Garbett KA, Shelton RC, Mirnics K. (2016)
An altered peripheral IL6 response in major depressive disorder.
Neurobiol Dis, 89: 46-54. [PMID:26804030]

5. Nishimoto N. (2006)
Interleukin-6 in rheumatoid arthritis.
Curr Opin Rheumatol, 18 (3): 277-81. [PMID:16582692]

6. Rovin BH, van Vollenhoven RF, Aranow C, Wagner C, Gordon R, Zhuang Y, Belkowski S, Hsu B. (2016)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.
Arthritis Rheumatol, 68 (9): 2174-83. [PMID:27110697]

7. Sun Y, Wang D, Salvadore G, Hsu B, Curran M, Casper C, Vermeulen J, Kent JM, Singh J, Drevets WC et al.. (2017)
The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Brain Behav Immun, 66: 156-164. [PMID:28676350]

8. Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, Davis HM, Zhou H. (2011)
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
Br J Clin Pharmacol, 72 (2): 270-81. [PMID:21392075]

9. Young JJ, Bruno D, Pomara N. (2014)
A review of the relationship between proinflammatory cytokines and major depressive disorder.
J Affect Disord, 169: 15-20. [PMID:25128861]

10. Zhang C, Wu Z, Zhao G, Wang F, Fang Y. (2016)
Identification of IL6 as a susceptibility gene for major depressive disorder.
Sci Rep, 6: 31264. [PMID:27502736]